In the present work, curcumin (30 mg/kg, p.o.)was used at a dose lower than that used to reduce liver fibrosis (100 mg/kg, p.o.)[25, 26], with the purpose of attenuating the damage generated by metabolism of α/β-AR blockers, creating an environment free of oxidative stress and inflammation with the probable activation of Nrf-2 and inhibition of NF-κB. In the present work, it was demonstrated that curcumin (30 mg/kg) did not reverse liver fibrosis, whereas it has been reported that curcumin (100 mg/kg) prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats [27]. This evidence concerns the gene NFE2L2 and cholestasis.